|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Statins, also known as 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, and antidepressant drugs are frequently used in combination due to the high and growing incidence of cardiovascular diseases and psychiatric disorders worldwide.
|
31587356 |
2020 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are a well-known class of drug with beneficial therapeutic effects in cardiovascular disease and lipid disorders and have potential use against cancer.
|
30203471 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Statins inhibit the action of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA), which is important in the synthesis of cholesterol and essential isoprenoid intermediates, thereby lowering circulating low-density lipoprotein cholesterol (LDL), a major risk factor for cardiovascular disease (CVD).
|
29935271 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Lovastatin is a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor that is clinically used for the prevention of cardiovascular diseases.
|
29207042 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are medications that have been used for decades to lower cholesterol and to prevent or treat cardiovascular diseases.
|
29238220 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
|
27959767 |
2016 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and are an important group of hypolipidaemic drugs, widely used in the treatment of hypercholesterolaemia and cardiovascular disease.
|
25444240 |
2015 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, is invariably used to treat cardiovascular diseases.
|
26539474 |
2015 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins) are prescribed to lower serum cholesterol levels and reduce the risk of CVD.
|
22688219 |
2013 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
The statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have been proven to be effective in lowering cholesterol and as anti-lipid agents against cardiovascular disease.
|
22134829 |
2012 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We analysed the sequence of the HMG-CoA reductase gene in DNA extracted from blood samples of 16 patients with cardiovascular disorders.
|
19187128 |
2009 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
|
18261733 |
2008 |